Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | APP | P05067 | 5/20 | 0.66 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560171 | 1.00 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1124069 | 0.87 | HSD17B3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL381477 | 0.87 | HSD17B3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2028512 | 0.86 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2028511 | 0.86 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11318713 | 0.84 | HSD17B3 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11318709 | 0.84 | HSD17B3 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27735435 | 0.84 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11152099 | 0.83 | TLR9 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9017237 | 0.82 | APP (0.95) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | claimed |
| WO-2008011074-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | claimed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | claimed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | claimed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | claimed |
| US-9040722-B2 | Photoelectric conversion device and photoelectric conversion device dye, and compound | ADEKA CORPORATION (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040722-B2 | Photoelectric conversion device and photoelectric conversion device dye, and compound | ADEKA CORPORATION (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8709821-B2 | Luminescent substrate for liciferase | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2014-04-29 | — | — | US | disclosed |
| US-8709821-B2 | Luminescent substrate for liciferase | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130186468-A1 | PHOTOELECTRIC CONVERSION DEVICE AND PHOTOELECTRIC CONVERSION DEVICE DYE, AND COMPOUND | ADEKA CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130186468-A1 | PHOTOELECTRIC CONVERSION DEVICE AND PHOTOELECTRIC CONVERSION DEVICE DYE, AND COMPOUND | ADEKA CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 7/4885HDAC4 14/4885HDAC1 1/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | HDAC3 5/4885HDAC4 13/4885HDAC1 1/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | HDAC3 7/4885HDAC4 16/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.